| Literature DB >> 27246829 |
Kieu-Suong Le1, Marie-Laure Thibult2, Sylvain Just-Landi3, Sonia Pastor4, Françoise Gondois-Rey4, Samuel Granjeaud4, Florence Broussais3, Reda Bouabdallah3, Renaud Colisson5, Christophe Caux5, Christine Ménétrier-Caux5, Dominique Leroux6, Luc Xerri7, Daniel Olive8.
Abstract
The prognosis of follicular lymphoma (FL) patients is suspected to be influenced by tumor-infiltrating regulatory T cells (Treg). The mechanism of Treg enrichment in FL and their impact on malignant FL B cells remains to be elucidated. We analyzed 46 fresh lymph node biopsy samples, including FL (n = 20), diffuse large B-cell lymphoma (n = 10), classical Hodgkin lymphoma (n = 9), and reactive lymphadenitis (n = 7). Using multicolor flow cytometry and cell sorting, we observed an accumulation of CD25(high)CD127(low/neg) Tregs in FL tissues. These Tregs comprised activated ICOS(+) Tregs that were able to suppress not only conventional T cells, but also FL B cells. These FL B cells were able to express ICOSL in vitro and to generate CD25(high)FoxP3(high) Tregs expressing ICOS. Treg generation was associated with ICOS/ICOSL engagement and was abrogated by antagonist anti-ICOS and anti-ICOSL antibodies. Interactions between Tregs and FL B cells resulted in ICOSL downregulation on FL B cells. Our results highlight a key role for Tregs in FL pathogenesis and suggest that targeting the ICOS/ICOSL pathway may be a promising immunotherapy for FL treatment. Cancer Res; 76(16); 4648-60. ©2016 AACR. ©2016 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27246829 DOI: 10.1158/0008-5472.CAN-15-0589
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701